Aduro using Stanford tech in next-generation LADDs
Aduro Biotech Inc. (NASDAQ:ADRO) said it gained an exclusive license to neoantigen identification technology from Stanford University. Aduro plans to use the technology to engineer personalized Listeria-based immunotherapies encoding multiple neoantigens, with a Phase I trial to treat GI cancers planned for this year.
Aduro said the deal gives it rights to bioinformatics algorithms and computational workflows for neoantigen identification and selection. It plans to incorporate antigens identified on patient tumors into its live-attenuated double-deleted (LADD) Listeria immunotherapy platform. The company said the personalized LADD (pLADD) therapies are designed to produce a general immune response through the presence of Listeria, as well as a tumor-specific response through neoantigen expression...